Lantern Pharma (LTRN) Other Working Capital Changes (2022 - 2026)

Lantern Pharma (LTRN) has reported Other Working Capital Changes for 5 consecutive years, with $363207.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes rose 944.99% year-over-year to $363207.0; the trailing twelve-month figure through Jun 2026 stood at -$42762.0 (up 94.61% YoY), and the FY2025 full-year result was -$554095.0, up 28.81% from the prior year.
• Other Working Capital Changes advanced to $363207.0 in Q2 2026 per LTRN's latest filing, from $49508.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $1.1 million in Q2 2022 and bottomed at -$901017.0 in Q1 2024.
• Historically, Other Working Capital Changes has averaged -$45961.3 across 5 years, with a median of -$39023.5 in 2023.
• The sharpest annual moves came in 2024 and 2026: Other Working Capital Changes plunged 865.92% in 2024, then jumped 944.99% in 2026.
• Over 5 years, Other Working Capital Changes stood at -$726028.0 in 2022, then jumped by 31.22% to -$499364.0 in 2023, then fell by 24.76% to -$623022.0 in 2024, then jumped by 35.09% to -$404392.0 in 2025, then surged by 189.82% to $363207.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $363207.0, $49508.0, and -$404392.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.